Compound Evidence File
#EC-2026-0817
NAD+
Filed under Peptides. The bureau holds 169 laboratory returns for this compound from 70 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
70 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Jan 2026 | 22 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 9.9 | 10.0 | 25 Jun 2026 | 5 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Dec 2025 | 20 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 10.0 | 10.0 | 12 Jan 2026 | 16 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Nov 2025 | 14 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 10.0 | 10.0 | 21 Mar 2026 | 3 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 18 Mar 2026 | 4 Jul 2026 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 10.0 | 10.0 | 10.0 | 7 May 2025 | 7 May 2025 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 10.0 | 10.0 | 10.0 | 27 Feb 2025 | 27 Feb 2025 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 17 Nov 2025 | 14 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Jan 2026 | 4 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Jan 2026 | 25 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Feb 2026 | 2 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Dec 2025 | 3 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Mar 2026 | 22 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 9.9 | 9.9 | 10.0 | 21 Apr 2026 | 3 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 25 Dec 2025 | 2 Apr 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 9.9 | 11 Mar 2026 | 12 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 25 Jan 2026 | 19 Mar 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 2 Mar 2026 | 8 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 7 May 2026 | 6 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 9.9 | 17 Jun 2026 | 2 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 9.9 | 23 Apr 2026 | 10 Jun 2026 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 9.7 | 9.7 | 9.7 | 6 May 2025 | 6 May 2025 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 9.7 | 9.7 | 9.7 | 13 Feb 2025 | 13 Feb 2025 |
| TCICASE #VI-2026-0650 | X | 1 | 9.7 | 9.7 | 9.7 | 7 May 2025 | 7 May 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 9.3 | 9.3 | 9.3 | 2 Apr 2025 | 2 Apr 2025 |
| Peptide PartnersCASE #VI-2026-0295 | X | 3 | 9.1 | 7.2 | 10.0 | 24 Apr 2025 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.8 | 8.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| BeiBangAnCASE #VI-2026-0899 | X | 1 | 8.8 | 8.8 | 8.8 | 6 May 2025 | 6 May 2025 |
| Peptide CraftersCASE #VI-2026-0994 | X | 2 | 8.6 | 8.1 | 9.2 | 24 Apr 2025 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.4 | 7.3 | 9.7 | 24 May 2026 | 24 May 2026 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 8.4 | 8.4 | 8.4 | 27 Feb 2025 | 27 Feb 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.3 | 6.9 | 9.8 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.2 | 6.9 | 9.1 | 24 May 2026 | 24 May 2026 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 8.2 | 8.2 | 8.2 | 3 Jun 2025 | 3 Jun 2025 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 8.2 | 8.2 | 8.2 | 7 May 2025 | 7 May 2025 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 7.8 | 7.8 | 7.8 | 20 Jun 2025 | 20 Jun 2025 |
| PeptiSlimCASE #VI-2026-0557 | X | 1 | 7.7 | 7.7 | 7.7 | 24 Apr 2025 | 24 Apr 2025 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 7.5 | 7.5 | 7.6 | 17 Dec 2024 | 26 Jan 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 7.5 | 7.5 | 7.5 | 7 May 2025 | 7 May 2025 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 7.5 | 7.5 | 7.5 | 9 Jun 2025 | 9 Jun 2025 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 10 | 7.3 | 3.5 | 9.6 | 24 Apr 2025 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 7.2 | 7.2 | 7.3 | 23 May 2026 | 23 May 2026 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 1 | 7.2 | 7.2 | 7.2 | 24 Apr 2025 | 24 Apr 2025 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 1 | 7.2 | 7.2 | 7.2 | 24 Apr 2025 | 24 Apr 2025 |
| Zztai PeptideCASE #VI-2026-0192 | C | 2 | 7.1 | 6.9 | 7.3 | 14 Jan 2025 | 24 May 2026 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 6.7 | 6.7 | 6.7 | 21 May 2025 | 21 May 2025 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 4 | 6.5 | 5.2 | 7.7 | 21 May 2025 | 24 May 2026 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 6.3 | 6.3 | 6.3 | 3 Jun 2025 | 3 Jun 2025 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 6.3 | 6.3 | 6.3 | 28 Mar 2025 | 28 Mar 2025 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 9 | 6.2 | 3.4 | 8.9 | 24 Apr 2025 | 19 Jan 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 2 | 6.2 | 5.3 | 7.0 | 9 Jun 2025 | 21 May 2026 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 6.1 | 6.1 | 6.1 | 28 Mar 2025 | 28 Mar 2025 |
| ScienceCASE #VI-2026-0636 | X | 1 | 6.0 | 6.0 | 6.0 | 28 Mar 2025 | 28 Mar 2025 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 5.8 | 5.8 | 5.8 | 13 Feb 2025 | 13 Feb 2025 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 5.7 | 5.7 | 5.7 | 13 Jun 2025 | 13 Jun 2025 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 5.5 | 5.5 | 5.5 | 21 May 2025 | 21 May 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 5.2 | 5.2 | 5.2 | 16 Mar 2025 | 16 Mar 2025 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 5.2 | 5.2 | 5.2 | 3 Jul 2025 | 3 Jul 2025 |
| Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 | X | 1 | 5.1 | 5.1 | 5.1 | 28 Mar 2025 | 28 Mar 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 4.8 | 4.8 | 4.8 | 16 Mar 2025 | 16 Mar 2025 |
| Dankang BioHealthCASE #VI-2026-0775 | X | 1 | 4.7 | 4.7 | 4.7 | 2 Jul 2025 | 2 Jul 2025 |
| YB PeptideCASE #VI-2026-0813 | X | 1 | 4.4 | 4.4 | 4.4 | 17 Dec 2024 | 17 Dec 2024 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 4.2 | 4.2 | 4.2 | 9 Jun 2025 | 9 Jun 2025 |
| Platinum CryoCASE #VI-2026-0406 | X | 2 | 4.0 | 3.5 | 4.4 | 6 May 2025 | 23 May 2026 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 3.1 | 3.1 | 3.1 | 27 Feb 2025 | 27 Feb 2025 |
| HK Fat CatCASE #VI-2026-0376 | X | 1 | 1.9 | 1.9 | 1.9 | 13 Jun 2025 | 13 Jun 2025 |
Open any subject to view the batch-level evidence for NAD+ alone.